Fresenius Kabi welcomed a “great testimonial of our Vision 2026 growth strategy” and a showcase of its “ambition to be leading in the biopharma segment” as it announced the European launch for the company’s Tyenne (tocilizumab) biosimilar to RoActemra – the first biosimilar tocilizumab product to reach the EU.
Endorsed by the European Medicines Agency’s Committee for Medicinal Products for Human Use in July, Tyenne in both subcutaneous (pre-filled syringe and autoinjector) and intravenous administrations was
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?